OPRL1
Nociceptin receptor
As of the edition of 20 October 2026, OPRL1 (nociceptin receptor, UniProt P41146) has 4 drugs tested at it and 3 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P41146
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 5
- Disease areas
- Mental health; Nervous system; Chemically induced; Lungs and airways; Bones, joints and muscles; Cancer; Hormones; Nutrition and metabolism
- Registered trials of its drugs
- 26
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 2 |
| Stopped | 2 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Cebranopadol | Stopped | Phase 3 | none listed |
| LY-2940094 | Stopped | Phase 2 | none listed |
| LY2940094 | Went quiet | Phase 2 | none listed |
| SCH-486757 | Went quiet | Phase 2 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Tris Pharma | Route A |
| Merck & Co. | Route A |
| BlackThorn Therapeutics | Route A |
The other 0 companies at OPRL1
In the product3 companies in all; 0 are not named here, and no score is.
See the 3 companies at OPRL1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.